» Articles » PMID: 6323188

Receptor Heterogeneity of Human Breast Cancer As Measured by Multiple Intratumoral Assays of Estrogen and Progesterone Receptor

Overview
Specialty Oncology
Date 1984 Mar 1
PMID 6323188
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple intratumoral tissue samples from the primary mass of 30 consecutive invasive breast cancer patients were assayed for estrogen receptor (ER) and progesterone receptor (PR) by the dextran-coated charcoal method following frozen section histopathological examination. Steroid receptor status of each sample was classified as positive (R+) or negative (R-), based only upon quantitative guide lines from the ER/PR results. Four out of 32 (12.5%) of the invasive cancers had an intratumoral sample classified as R+ and one sample as R-. R+ invasive ductal carcinomas has a highly significant degree of tubule formation (P = 0.005) when compared with R- invasive ductal cancers. While the quantitative ER content (r = 0.18) and the degree of quantitative variation in ER content (P = 0.04) did not correlate with the tumor cellularity of the individual samples, tumor cellularity (P = 0.005) and ER content (P = 0.005) were lower in the samples from the tumor border than from the central tumor samples. Variations in ER and PR content may be found on a regional basis within a breast tumor mass resulting from heterogeneity of tumor subpopulations and/or differences in tumor cellularity.

Citing Articles

Ultrasound-based radiomics model for predicting molecular biomarkers in breast cancer.

Xu R, You T, Liu C, Lin Q, Guo Q, Zhong G Front Oncol. 2023; 13:1216446.

PMID: 37583930 PMC: 10424446. DOI: 10.3389/fonc.2023.1216446.


The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.

Andrade de Oliveira K, Sengupta S, Yadav A, Clarke R Front Endocrinol (Lausanne). 2023; 14:1083048.

PMID: 36909339 PMC: 9997040. DOI: 10.3389/fendo.2023.1083048.


Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review.

Kavan S, Kruse T, Vogsen M, Hildebrandt M, Thomassen M Cancer Metastasis Rev. 2022; 41(2):433-446.

PMID: 35286542 DOI: 10.1007/s10555-022-10023-9.


Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer.

Inda M, van Swinderen P, van Brussel A, Moelans C, Verhaegh W, van Zon H Cancers (Basel). 2021; 13(6).

PMID: 33809754 PMC: 8002348. DOI: 10.3390/cancers13061345.


Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.

Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G Cells. 2020; 9(12).

PMID: 33316954 PMC: 7764472. DOI: 10.3390/cells9122644.